New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
09:20 EDTAXL, SREV, RXII, OPEN, SQNM, RBS, NTRI, SQI, INVN, AVNR, MRK, CVX, BCOR, BIRT, IMMU, ISRG, ECYTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Royal Bank of Scotland (RBS), up 9%... Sequenom (SQNM), up 8.2%... Nutrisystem (NTRI), up 11.5%... American Axle (AXL), up 2.9%. ALSO HIGHER: Wynn Resorts (WYNN), up 4% after earnings, shares upgraded at Sterne Agee... Avanir (AVNR), up 3.7% after upgraded at Mizuho... RXi Pharmaceuticals (RXII), up 27.4% after announcing results from study of RXI-109... Intuitive Surgical (ISRG), up 4% after announcing accelerated share repurchase. DOWN AFTER EARNINGS: Chevron (CVX), down 1%... OpenTable (OPEN), down 3.4%... Actuate (BIRT), down 18.2%... SciQuest (SQI), down 20%... ServiceSource (SREV), down 15.2%. ALSO LOWER: Endocyte (ECYT), down 60% after announcing DSMB recommends vintafolide PROCEED trial be stopped. The drug is being developed in partnership with Merck (MRK)... Immunomedics (IMMU), down 16% after filing to sell $30M worth of common stock in a spot secondary offering... InvenSense (INVN), down 9.3% after downgraded at Needham following the company's Q4 earnings report... Blucora (BCOR), down 10% after earnings, downgrade at Craig-Hallum.
News For CVX;RBS;ECYT;MRK;SQNM;ISRG;AVNR;OPEN;IMMU;INVN;RXII;BIRT;SQI;SREV;BCOR;NTRI;AXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
09:59 EDTINVNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:54 EDTAXLAmerican Axle targets FY15-FY17 annual sales to grow at CAGR in excess of 5%
Subscribe for More Information
09:52 EDTAXLAmerican Axle sees FY15 revenue $4B-$4.1B, consensus $4.07B
This sales projection is based on the anticipated launch schedule of programs in AAM's new and incremental business backlog and the assumption that the U.S. Seasonally Adjusted Annual Rate of sales is in the range of 16.5M-17M light vehicle units for the full year 2015. Sees FY15 ABITDA $550M-$575M. Sees FY15 free cash flow $175M-$200M. Sees FY15 CapEx to be 5% of sales in 2015.
08:27 EDTMRKNGM Biopharmaceuticals to hold a teleconference
NGM Biopharm discusses the strategic collaboration with Merck to discover, develop and commercialize novel biologic therapeutics on a teleconference to be held on February 23 at 9:30 am. Webcast Link
08:14 EDTAXLAmerican Axle reports Q4 EPS 17c, may not compare to consensus 54c
Subscribe for More Information
08:04 EDTAXLAmerican Axle reports Q4 non-GAM sales up 13% to $317.2M
Subscribe for More Information
08:04 EDTAXLAmerican Axle reports Q4 net income 17c, not comparable to consensus 54c
Reports Q4 revenue $939.5M, consensus $924.29M. In the fourth quarter, AAM's results reflect the impact of a non-cash charge of $35.5M related to the 2014 Pension Payout Offer. This compares to net income of $29.8M, or 39c per share, in the fourth quarter of 2013.
07:56 EDTINVNInvenSense initiated with an Outperform at Barrington
Subscribe for More Information
07:52 EDTAXLAmerican Axle to amend 10-Q for period ended September 30, 2014
American Axle said in a filing that on February 19, the Audit Committee of the Board of Directors of American Axle & Manufacturing Holdings, after discussion with management and the company’s independent registered public accounting firm, Deloitte & Touche LLP, concluded that the financial statements contained in the company’s Quarterly Report on Form 10-Q for the period ended September 30, 2014, as previously filed with the SEC on October 31, 2014, should no longer be relied upon. American Axle says "In connection with the preparation of our consolidated financial statements for the year ended December 31, 2014, we determined that entries recorded in the third quarter of 2014 to reduce certain accrued accounts payable balances by $8.4M were previously recorded as a reduction of cost of goods sold but should have been recorded as an adjustment to opening accumulated deficit because the amounts giving rise to the correction originated in periods prior to January 1, 2012. While management determined that it was necessary to restate the September 30, 2014 interim period and revise management’s conclusion regarding the effectiveness of disclosure controls and procedures as a result of a material weakness in internal controls over financial reporting, the effect of correcting these errors was not material to opening accumulated deficit as of January 1, 2012. The cumulative impact of the error was a decrease of $6.9M in opening accumulated deficit as of January 1, 2012.As a result of the foregoing, AAM will amend our Form 10-Q for the interim period ended September 30, 2014 to restate our previously issued financial statements. The Form 10-Q/A will be filed on February 23, 2015."
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250M to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
February 22, 2015
13:55 EDTCVXChevron relinquishes Romanian shale-gas interests, WSJ says
Subscribe for More Information
11:59 EDTCVXUSW to expand ULP oil strike
The United Steelworkers, USW, announced that it will expand its unfair labor practice strike, ULP, by launching a work stoppage tonight at midnight at the Motiva Enterprises refinery in Port Arthur, Texas. This refinery, a 50-50 joint venture between Shell Oil Company and Saudi Refining, produces more than 600,000 barrels per day. In addition, 24 hour strike notices were delivered at Motiva’s two Louisiana refineries in Convent and Norco as well as at the Shell Chemical plant in Norco. Capacity at these facilities is 235,000 and 238,000. These refineries are also jointly operated by Royal Dutch Shell and Saudi Refining, Inc. of Saudi Arabia. “The industry’s refusal to meaningfully address safety issues through good faith bargaining gave us no other option but to expand our work stoppage,” said USW International President Leo W. Gerard. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
February 20, 2015
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
14:34 EDTIMMUImmunomedics presents updated results with sacituzumab govitecan in lung cancer
Immunomedics announced that 33% of patients with small cell lung cancer, SCLC, and 31% with non-small cell lung cancer, NSCLC, had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, ADC. Including patients that reported stable disease as their best response, the ADC controls the progression of the cancer in 75% and 56% of NSCLC and SCLC patients, respectively. These patients had either failed to respond to their last lung cancer therapies or their cancer had returned or progressed. Dr. Francois Wilhelm, Chief Medical Officer, presented the updated results at the 15th Annual Targeted Therapies of Lung Cancer Meeting, an invitation-only meeting sponsored by The International Association for the Study of Lung Cancer.
14:21 EDTRBSS&P reportedly says Greece contagion not a major risk, Reuters reports
The risk of contagion spreading from Greece to other European countries is not that large, a German newspaper quoted S&P's chief sovereign ratings officer as saying, according to Reuters. The euro zone would be able to handle an exit of the bloc by Greece, the ratings officer was quoted as saying, Reuters reported. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
06:58 EDTCVXU.S. oil prices tumble after inventory data released, Reuters says
Subscribe for More Information
06:04 EDTRBSFCA to investigate investment and corporate banking
Subscribe for More Information
February 17, 2015
06:58 EDTCVXBrent oil reaches $62 per barrel, Reuters reports
Driven higher by Middle East turbulence, the price of brent crude oil reached $62 per barrel today, close to its 2015 high, according to Reuters. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
February 16, 2015
11:21 EDTCVXChevron reaches settlement with principal funder of lawsuit in Ecuador
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use